Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
Department of Health Services, University of Washington School of Public Health, Seattle, Washington, USA.
Subst Abus. 2019;40(3):268-277. doi: 10.1080/08897077.2018.1544964. Epub 2019 Jan 18.
Cannabis use disorders (CUDs) have increased with more individuals using cannabis, yet few receive treatment. Health systems have adopted the Healthcare Effectiveness Data and Information Set (HEDIS) quality measures of initiation and engagement in alcohol and other drug (AOD) dependence treatment, but little is known about the performance of these among patients with CUDs. This cohort study utilized electronic health records and claims data from 7 health care systems to identify patients with documentation of a new index CUD diagnosis (no AOD diagnosis ≤60 days prior) from International Classification of Diseases, Ninth revision, codes (October 1, 2014, to August 31, 2015). The adjusted prevalence of each outcome (initiation, engagement, and a composite of both) was estimated from generalized linear regression models, across index identification settings (inpatient, emergency department, primary care, addiction treatment, and mental health/psychiatry), AOD comorbidity (patients with CUD only and CUD plus other AOD diagnoses), and patient characteristics. Among 15,202 patients with an index CUD diagnosis, 30.0% (95% confidence interval [CI]: 29.2-30.7%) initiated, 6.9% (95% CI: 6.2-7.7%) engaged among initiated, and 2.1% (95% CI: 1.9-2.3%) overall both initiated and engaged in treatment. The adjusted prevalence of outcomes varied across index identification settings and was highest among patients diagnosed in addiction treatment, with 25.0% (95% CI: 22.5-27.6%) initiated, 40.9% (95% CI: 34.8-47.0%) engaged, and 12.5% (95% CI: 10.0-15.1%) initiated and engaged. The adjusted prevalence of each outcome was generally highest among patients with CUD plus other AOD diagnosis at index diagnosis compared with those with CUD only, overall and across index identification settings, and was lowest among uninsured and older patients. Among patients with a new CUD diagnosis, the proportion meeting HEDIS criteria for initiation and/or engagement in AOD treatment was low and demonstrated variation across index diagnosis settings, AOD comorbidity, and patient characteristics, pointing to opportunities for improvement.
大麻使用障碍 (CUD) 在更多人使用大麻的情况下有所增加,但很少有人接受治疗。医疗保健系统已经采用了医疗保健效果数据和信息集 (HEDIS) 酒精和其他药物 (AOD) 依赖治疗的起始和参与质量指标,但对于 CUD 患者的这些指标的表现知之甚少。本队列研究利用来自 7 个医疗保健系统的电子健康记录和索赔数据,从国际疾病分类,第九版 (ICD-9) 代码中确定了有新的指数 CUD 诊断记录的患者(无 AOD 诊断≤60 天)(2014 年 10 月 1 日至 2015 年 8 月 31 日)。从广义线性回归模型估计了每个结局(起始、参与和两者的组合)的调整后患病率,跨越指数识别设置(住院、急诊、初级保健、成瘾治疗和心理健康/精神病学)、AOD 合并症(仅 CUD 患者和 CUD 加其他 AOD 诊断)和患者特征。在 15202 名有指数 CUD 诊断的患者中,30.0%(95%置信区间 [CI]:29.2-30.7%)开始治疗,6.9%(95% CI:6.2-7.7%)开始治疗,2.1%(95% CI:1.9-2.3%)总体上开始和参与治疗。结局的调整后患病率因指数识别设置而异,在诊断为成瘾治疗的患者中最高,起始率为 25.0%(95% CI:22.5-27.6%),参与率为 40.9%(95% CI:34.8-47.0%),开始和参与率为 12.5%(95% CI:10.0-15.1%)。总体而言,与仅 CUD 患者相比,指数诊断时患有 CUD 加其他 AOD 诊断的患者的每个结局的调整后患病率通常最高,在所有指数识别设置中也是如此,而无保险和年龄较大的患者的患病率最低。在新诊断为 CUD 的患者中,符合 HEDIS 酒精和其他药物治疗起始和/或参与标准的比例较低,并且在指数诊断设置、AOD 合并症和患者特征方面存在差异,这表明有改进的机会。